journal article·2025-06

Deciphering pericyte-induced temozolomide resistance in glioblastoma with a 3D microphysiological system mimicking the biomechanical properties of brain tissue

Surjendu Maity, Christopher Jewell, Can Yilgor, Satoru Kawakita, Saurabh Sharma, Alejandro Gomez, Marvin Mecwan, Natashya Falcone, Menekse Ermis, Mahsa Monirizad, Negar Hosseinzadeh Kouchehbaghi, Fatemeh Zehtabi, Danial Khorsandi, Mehmet Remzi Dokmeci, Diogo Moniz-Garcia, Alfredo Quiñones-Hinojosa, Ali Khademhosseini, Vadim Jucaud

Acta Biomaterialia· Volume 200
Publisher page

Abstract

Glioblastoma (GBM) is a highly aggressive malignancy with a poor prognosis and frequent resistance to temozolomide (TMZ), the standard-of-care chemotherapy. The complex mechanisms underlying GBM chemoresistance, particularly the role of pericytes, remain poorly understood due to the lack of physiologically relevant in vitro models replicating the complex tumor microenvironment (TME). Here, we present a biomimetic 3D GBM microphysiological system that replicates the biomechanical properties of brain tissue (G'∼800Pa, G"∼100Pa) and enables the study of pericyte-mediated TMZ resistance. GBM spheroids (U87, LN229, PDM140) were cultured alone or co-cultured with pericytes in a composite hydrogel for 14 days and remained viable and proliferative. In response to TMZ, PDM140 was the most sensitive (IC50=73μM), followed by LN229 (IC50=278μM) and U87 (IC50=446μM). Co-culture with pericytes significantly increased GBM spheroid viability by 22.7% (PDM140), 32.5% (LN229), and 22.1% (U87), confirming pericyte-induced TMZ resistance. Notably, pericytes exhibited a 160-fold upregulation of C-C motif chemokine ligand 5 (CCL5) upon TMZ treatment, implicating the CCL5-mediated pathway in chemoresistance. This innovative brain-mimicking 3D GBM model provides a physiologically relevant platform for studying tumor-pericyte interactions and testing therapeutic strategies targeting CCL5-mediated resistance mechanisms in GBM. STATEMENT OF SIGNIFICANCE: We developed a multicellular 3D glioblastoma microphysiological system mimicking the physicochemical properties of brain tissues and pericyte-mediated TMZ resistance that can be used to screen for standard-of-care chemotherapy. This advanced hydrogel-based platform demonstrated the critical role of the glioblastoma tumor microenvironment in modulating chemotherapy sensitivity, particularly the pericyte-induced CCL5-CCR5 paracrine axis that can lead to the identification of therapeutic targets within the CCL5-CCR5 pathway toward more effective treatments disrupting these resistance mechanisms. Overall, the proposed 3D glioblastoma microphysiological system can transform drug screening and personalized treatment for GBM by offering ethical and cost-effective alternatives to animal testing and more effective drug screening and discovery efforts, ultimately improving GBM patient outcomes.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Glioma Diagnosis and Treatment · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary10.1007/s00401-016-1545-1 ↗
2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma10.1056/NEJMoa043330 ↗
3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial10.1016/S1470-2045(09)70025-7 ↗
4. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-201610.1093/neuonc/noz150 ↗
5. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-201010.1093/neuonc/not151 ↗
7. Temozolomide in malignant gliomas: current use and future targets10.1007/s00280-009-1050-5 ↗
8. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma10.1186/s13046-019-1139-6 ↗
9. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma10.1212/WNL.0000000000003809 ↗
10. Mechanisms and therapeutic implications of hypermutation in gliomas10.1038/s41586-020-2209-9 ↗
11. Temozolomide: An Updated Overview of Resistance Mechanisms
12. A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase10.4103/glioma.glioma_3_19 ↗
13. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression10.1371/journal.pone.0140131 ↗
14. Temozolomide: mechanisms of action, repair and resistance10.2174/1874467211205010102 ↗
15. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma10.1016/j.cell.2019.06.024 ↗
16. The updated landscape of tumor microenvironment and drug repurposing10.1038/s41392-020-00280-x ↗
17. Old Stars and New Players in the Brain Tumor Microenvironment10.3389/fncel.2021.709917 ↗
18. Neuronal and tumourigenic boundaries of glioblastoma plasticity10.1016/j.trecan.2022.10.010 ↗
19. Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches
20. The Extracellular Matrix in Glioblastomas: A Glance at Its Structural Modifications in Shaping the Tumoral Microenvironment-A Systematic Review10.3390/cancers15061879 ↗
21. Physics of Brain Cancer: Multiscale Alterations of Glioblastoma Cells under Extracellular Matrix Stiffening10.3390/pharmaceutics14051031 ↗
22. The Double Play by Microenvironment and Blood-Brain Barrier10.3390/ijms19102879 ↗
23. S. De Vleeschouwer, G. Bergers, Glioblastoma: to target the tumor cell or the microenvironment?, Exon Publications (2017) 315-340.10.15586/codon.glioblastoma.2017.ch16 ↗
24. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions10.1007/978-3-030-16908-4_2 ↗
25. Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer’s disease10.1093/neuonc/nox058 ↗
26. Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy10.1016/j.stem.2017.10.002 ↗
27. Pericytes in the tumor microenvironment10.1016/j.canlet.2023.216074 ↗
28. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling10.1038/s41422-021-00528-3 ↗
29. Microvascular fractal dimension predicts prognosis and response to chemotherapy in glioblastoma: an automatic image analysis study10.1038/s41374-018-0055-2 ↗
30. The Intricate Expression of CC Chemokines in Glial Tumors: Evidence for Involvement of CCL2 and CCL5 but Not CCL11
31. Pericyte-Glioblastoma Cell Interaction: A Key Target to Prevent Glioblastoma Progression10.3390/cells12091324 ↗
32. Vitro Glioblastoma Models: A Journey into the Third Dimension10.3390/cancers13102449 ↗
33. 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions10.1016/j.trecan.2020.10.009 ↗
34. Functional drug screening assay reveals potential glioma therapeutics10.1089/adt.2010.0324 ↗
35. Organotypic slice cultures: a technique has come of age10.1016/S0166-2236(97)01122-3 ↗
36. Neurosphere culture and human organotypic model to evaluate brain tumor stem cells10.1007/978-1-59745-280-9_6 ↗
37. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies10.1093/noajnl/vdab100 ↗
38. The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development10.1016/j.coph.2019.09.007 ↗
39. Patient-Derived Microphysiological Systems for Precision Medicine
40. Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients10.1002/adhm.202302331 ↗
41. Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels10.1002/adhm.202400779 ↗
42. High-resolution tomographic analysis of in vitro 3D glioblastoma tumor model under long-term drug treatment10.1126/sciadv.aay7513 ↗
43. 3D cancer models: One step closer to in vitro human studies10.3389/fimmu.2023.1175503 ↗
44. Engineered In Vitro Tumor Model Recapitulates Molecular Signatures of Invasion in Glioblastoma10.1021/acsmaterialsau.3c00029 ↗
45. Three-dimensional culture models to study glioblastoma - current trends and future perspectives10.1016/j.coph.2021.08.019 ↗
46. Glioblastoma, from disease understanding towards optimal cell-based in vitro models10.1007/s13402-022-00684-7 ↗
47. Practical Review on Preclinical Human 3D Glioblastoma Models: Advances and Challenges for Clinical Translation10.3390/cancers12092347 ↗
48. Mechanical properties of brain tissue by indentation: interregional variation10.1016/j.jmbbm.2009.09.001 ↗
49. Anisotropic constitutive equations and experimental tensile behavior of brain tissue10.1007/s10237-005-0007-9 ↗
50. Gelatin methacryloyl and its hydrogels with an exceptional degree of controllability and batch-to-batch consistency10.1038/s41598-019-42186-x ↗
51. Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels10.1016/j.biomaterials.2015.08.045 ↗
52. Gelatin methacrylate hydrogels culture model for glioblastoma cells enriches for mesenchymal-like state and models interactions with immune cells10.1038/s41598-021-97059-z ↗
53. The Combined Influence of Hydrogel Stiffness and Matrix-Bound Hyaluronic Acid Content on Glioblastoma Invasion10.1002/mabi.201700018 ↗
54. Association of collagen architecture with glioblastoma patient survival10.3171/2016.6.JNS152797 ↗
55. Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels10.1021/am402097j ↗
56. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity10.1038/s41392-021-00830-x ↗
57. In vitro biomimetic models for glioblastoma-a promising tool for drug response studies10.1016/j.drup.2021.100753 ↗
58. Engineered Hydrogels for Brain Tumor Culture and Therapy10.1007/s42242-020-00084-6 ↗
59. Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer10.1016/j.bioactmat.2023.02.005 ↗
60. Oil-in-microgel strategy for enzymatic-triggered release of hydrophobic drugs10.1016/j.jcis.2017.01.029 ↗
61. In situ photocrosslinkable hyaluronic acid-based surgical glue with tunable mechanical properties and high adhesive strength10.1002/pola.29290 ↗
62. Swellable Gelatin Methacryloyl Microneedles for Extraction of Interstitial Skin Fluid toward Minimally Invasive Monitoring of Urea10.1002/mabi.202000195 ↗
63. Reduced Graphene Oxide Incorporated GelMA Hydrogel Promotes Angiogenesis For Wound Healing Applications10.2147/IJN.S218120 ↗
64. Determining rock pore space using image processing methods10.7494/geol.2013.39.1.45 ↗
65. The Use of 3D Polylactic Acid Scaffolds with Hydroxyapatite/Alginate Composite Injection and Mesenchymal Stem Cells as Laminoplasty Spacers in Rabbits10.3390/polym14163292 ↗
66. simulating transport and adsorption of organic contaminants in 3D porous activated carbon block media
67. An optimized procedure to develop a 3-dimensional microfluidic hydrogel with parallel transport networks10.1002/cnm.3154 ↗
68. Insulin diffusion and self-association characterized by real-time UV imaging and Taylor dispersion analysis10.1016/j.jpba.2014.01.022 ↗
69. Self-Organized Implanting of Micro/Nanofiltration Membranes in Advanced Flow μ-Reactors10.1021/acsami.1c01078 ↗
70. Real-time transport kinetics of drug encapsulated nanoparticles into apoptotic cancer cells inside microchannels10.1088/1361-6528/ac2391 ↗
71. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis
72. Compression stiffening of brain and its effect on mechanosensing by glioma cells10.1088/1367-2630/16/7/075002 ↗
73. Mechanical Characterization of Human Brain Tissue and Soft Dynamic Gels Exhibiting Electromechanical Neuro-Mimicry10.1002/adhm.201900068 ↗
74. Glioblastoma-derived cells in vitro unveil the spectrum of drug resistance capability - comparative study of tumour chemosensitivity in different culture systems10.1042/BSR20170058 ↗
75. The Emerging Roles of Pericytes in Modulating Tumor Microenvironment
76. Multicellular tumor spheroids: an underestimated tool is catching up again10.1016/j.jbiotec.2010.01.012 ↗
77. Composite Hydrogels in Three-Dimensional in vitro Models10.3389/fbioe.2020.00611 ↗
78. A practical guide to hydrogels for cell culture10.1038/nmeth.3839 ↗
79. Engineering Hydrogel Microenvironments to Recapitulate the Stem Cell Niche10.1146/annurev-bioeng-062117-120954 ↗
80. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma10.1021/bi00267a025 ↗
81. Hybrid Methacrylated Gelatin and Hyaluronic Acid Hydrogel Scaffolds. Preparation and Systematic Characterization for Prospective Tissue Engineering Applications10.3390/ijms22136758 ↗
82. Functionalization, preparation and use of cell-laden gelatin methacryloyl-based hydrogels as modular tissue culture platforms10.1038/nprot.2016.037 ↗
83. Drug-Eluting Shear-Thinning Hydrogel for the Delivery of Chemo- and Immunotherapeutic Agents for the Treatment of Hepatocellular Carcinoma
84. Bio-printing of aligned GelMa-based cell-laden structure for muscle tissue regeneration10.1016/j.bioactmat.2021.06.031 ↗
85. Mussel-inspired cryogels for promoting wound regeneration through photobiostimulation, modulating inflammatory responses and suppressing bacterial invasion10.1039/C9NR03095F ↗
86. A simple layer-stacking technique to generate biomolecular and mechanical gradients in photocrosslinkable hydrogels10.1088/1758-5090/ab08b5 ↗
87. Biomaterial-based in vitro 3D modeling of glioblastoma multiforme10.1016/j.cpt.2023.01.002 ↗
88. Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies10.1186/s12885-021-08972-5 ↗
89. Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump
90. Spheroids as a Type of Three-Dimensional Cell Cultures-Examples of Methods of Preparation and the Most Important Application10.3390/ijms21176225 ↗
91. 3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy10.3390/organoids1020012 ↗
92. Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers10.3390/ijms241814256 ↗
93. Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress10.3389/fmolb.2020.620677 ↗
94. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme10.2478/raon-2019-0057 ↗
95. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells10.1038/s41598-017-06851-3 ↗
96. PTEN downregulation induces apoptosis and cell cycle arrest in uterine cervical cancer cells10.3892/etm.2021.10534 ↗
97. OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth10.1016/j.tranon.2018.10.002 ↗
98. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma10.1016/j.bbrc.2018.01.093 ↗
99. Matrix crosslinking forces tumor progression by enhancing integrin signaling10.1016/j.cell.2009.10.027 ↗
100. The brain tumor microenvironment10.1002/glia.21136 ↗